Guggenheim Issues Positive Forecast for Compass Therapeutics (NASDAQ:CMPX) Stock Price

Key Points

• Guggenheim has raised the price target for Compass Therapeutics (NASDAQ:CMPX) from $10.00 to $12.00, indicating a potential upside of 259.28% from its current price, while maintaining a "buy" rating on the stock.
• The stock has recently seen a 23.7% increase in value, with shares opening at $3.34, reflecting increased optimism among analysts, as evidenced by their forecasts.
• Compass Therapeutics reported earnings per share of ($0.14) for the last quarter, slightly missing the consensus estimate, and is projected to post -0.36 earnings per share for the current year.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) had its price target upped by equities research analysts at Guggenheim from $10.00 to $12.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Guggenheim's price objective points to a potential upside of 259.28% from the company's current price.

Other equities research analysts also recently issued research reports about the company. D. Boral Capital reaffirmed a "buy" rating and set a $32.00 price objective on shares of Compass Therapeutics in a research report on Monday, April 28th. HC Wainwright reaffirmed a "buy" rating and set a $24.00 price objective on shares of Compass Therapeutics in a research report on Monday, April 21st. Finally, Raymond James Financial raised Compass Therapeutics to an "outperform" rating and set a $9.00 price objective on the stock in a research report on Tuesday, July 1st. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $12.89.

Compass Therapeutics Stock Up 23.7%

Shares of Compass Therapeutics stock opened at $3.34 on Tuesday. The stock's fifty day moving average is $2.74 and its two-hundred day moving average is $2.49. The company has a market capitalization of $461.86 million, a PE ratio of -8.15 and a beta of 1.49. Compass Therapeutics has a 52 week low of $1.12 and a 52 week high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). As a group, research analysts anticipate that Compass Therapeutics will post -0.36 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CMPX. Creative Planning purchased a new position in Compass Therapeutics during the second quarter valued at approximately $30,000. Simplicity Wealth LLC raised its position in Compass Therapeutics by 81.8% during the second quarter. Simplicity Wealth LLC now owns 84,636 shares of the company's stock valued at $220,000 after acquiring an additional 38,093 shares in the last quarter. Strs Ohio purchased a new position in Compass Therapeutics during the first quarter valued at approximately $34,000. Birchview Capital LP purchased a new position in Compass Therapeutics during the first quarter valued at approximately $46,000. Finally, Propel Bio Management LLC purchased a new position in Compass Therapeutics during the first quarter valued at approximately $434,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.